developed, the industry has used many types of controls and has required its practitioners to adjust to different measurement methods. Historically, the measures used have been cost focused. But today purchasers and end users of the managed care product are turning the focus more toward quality measures, with a greater emphasis on comparing and contrasting physicians, health plans, programs, and processes. Consumers are demanding better performance from managed-'care and are looking for quantifiable results. Being a successful player in the managed care market in the future will require careful expenditures and thoughtful evaluations of how the business of health care actually affects the population beneath its umbrella. The methods by which this will be defined include pharmacoeconomics and outcomes evaluations. The pharmacist will playa key role as managed care organizations (MCOs) increase their use of formal measurements. Even in the early, rudimentary days (not achieving cost reductions through the elimination of duplicate prescriptions, assuring beneficiary match, controlling quantities dispensed, and preventing unnecessary waste. Later refinements of
Some managed care plans are introducing formulary variations to answer the concern. For example, some plans are introducing a provision for members to select nonpreferred agents, but at a higher copayment, offsetting a potential loss to the plan and alleviating the point-of-service hassle. But this is a temporary solution. Until valid outcomes evaluations or sound pharmacoeconomic processes are applied consistently to formulary decision making, the attacks, controversy, and protective legislation will continue. 
CHANGING PARADIGMS

EMPLOYER/PURCHASER ISSUES
In the future, the purchasers of health care-largely employers-'-will be looking for more than the best price. showing that a one-day stay isn't at least as good as a two-day stay, then it deserves to be legislated." She also discussed the pharmacy benefit as a point of dissatisfaction for employees. In 1998 PBGH expects to call for some uniformity in formularies among their contracted health plans. Good outcomes data and the application of pharmacoeconomics in the decision-making process for formulary composition will be important parameters for plans to present. Losing members has many significant ramifications. For example, it can cost as much as five times more to recruit a member than to retain a member. The problem of disenrollment is more than financial. In an overall scheme to provide quality health care services to a defined population, the disenrollment factor affects programs meant to assure quality initiatives. Managing a population of asthmatics or diabetics becomes more difficult as members, and their outcomes results, leave the system. There is concern that this recent move by the FDA to regulate cqst -effective- 
PATIENTS DEMAND MORE
Formulary Decision Making
Pharmacists also will benefit from the ability to use outcome data for making formulary decisions using decision 
CHALLENGES AND OPPORTUNITIES
The managed care pharmacist will need to find partners with credibility, competence, and resources to conduct outcomes evaluations that benefit the health care industry overall. These will Organizations that align themselves in strategic partnerships to move forward will be the ultimate winners. This is a call to action. Determine needs, look for partners, and get involved in outcomes research. The dividends will be large, and pharmacists are clearly among the most qualified professionals to accomplish these agendas.
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